Literature DB >> 19323044

Construction and characterization of an unmarked aroC deletion mutant of Burkholderia pseudomallei strain A2.

Thitima Srilunchang1, Tanakorn Proungvitaya, Surasak Wongratanacheewin, Richard Strugnell, Preecha Homchampa.   

Abstract

Using a sucrose counter-selection strategy, we have constructed an unmarked aroC deletion mutant of B. pseudomallei strain A2 in order to investigate the possibility of an effective live-attenuated vaccine. The aroC deletion in the resultant mutant, designated A2DeltaaroC, was confirmed by PCR, Southern hybridization and failure of the mutant to grow in a defined medium without aromatic compounds. Compared to the parental wild type strain, A2DeltaaroC was highly attenuated for virulence following intraperitoneal introduction into BALB/c and C57BL/6 mice. BALB/c mice immunized intraperitoneally with A2DeltaaroC were not protected against a challenge dose of 500 cfu (25 x LD50) of the parental strain A2, whereas C57BL/6 mice similarly immunized intraperitoneally with A2DeltaaroC were significantly protected against a challenge dose of 6,000 cfu (20 x LD50).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19323044

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  20 in total

Review 1.  Novel multi-component vaccine approaches for Burkholderia pseudomallei.

Authors:  L Morici; A G Torres; R W Titball
Journal:  Clin Exp Immunol       Date:  2019-04-08       Impact factor: 4.330

2.  A Burkholderia pseudomallei deltapurM mutant is avirulent in immunocompetent and immunodeficient animals: candidate strain for exclusion from select-agent lists.

Authors:  Katie L Propst; Takehiko Mima; Kyoung-Hee Choi; Steven W Dow; Herbert P Schweizer
Journal:  Infect Immun       Date:  2010-04-19       Impact factor: 3.441

3.  Prediction of Burkholderia pseudomallei DsbA substrates identifies potential virulence factors and vaccine targets.

Authors:  Ben Vezina; Guillaume A Petit; Jennifer L Martin; Maria A Halili
Journal:  PLoS One       Date:  2020-11-20       Impact factor: 3.240

4.  Protection against experimental melioidosis following immunization with live Burkholderia thailandensis expressing a manno-heptose capsule.

Authors:  Andrew E Scott; Thomas R Laws; Riccardo V D'Elia; Margaret G M Stokes; Tannistha Nandi; E Diane Williamson; Patrick Tan; Joann L Prior; Timothy P Atkins
Journal:  Clin Vaccine Immunol       Date:  2013-05-15

5.  Systematic annotation and analysis of "virmugens"-virulence factors whose mutants can be used as live attenuated vaccines.

Authors:  Rebecca Racz; Monica Chung; Zuoshuang Xiang; Yongqun He
Journal:  Vaccine       Date:  2012-12-06       Impact factor: 3.641

6.  Correlates of immune protection following cutaneous immunization with an attenuated Burkholderia pseudomallei vaccine.

Authors:  Ediane B Silva; Andrew Goodyear; Marjorie D Sutherland; Nicole L Podnecky; Mercedes Gonzalez-Juarrero; Herbert P Schweizer; Steven W Dow
Journal:  Infect Immun       Date:  2013-10-07       Impact factor: 3.441

7.  Impact of homologous and non-homologous recombination in the genomic evolution of Escherichia coli.

Authors:  Xavier Didelot; Guillaume Méric; Daniel Falush; Aaron E Darling
Journal:  BMC Genomics       Date:  2012-06-19       Impact factor: 3.969

Review 8.  Burkholderia vaccines: are we moving forward?

Authors:  Leang-Chung Choh; Guang-Han Ong; Kumutha M Vellasamy; Kaveena Kalaiselvam; Wen-Tyng Kang; Anis R Al-Maleki; Vanitha Mariappan; Jamuna Vadivelu
Journal:  Front Cell Infect Microbiol       Date:  2013-02-05       Impact factor: 5.293

Review 9.  Development of Burkholderia mallei and pseudomallei vaccines.

Authors:  Ediane B Silva; Steven W Dow
Journal:  Front Cell Infect Microbiol       Date:  2013-03-11       Impact factor: 5.293

10.  Vaccines for the Prevention of Melioidosis and Glanders.

Authors:  Monica M Johnson; Kristy M Ainslie
Journal:  Curr Trop Med Rep       Date:  2017-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.